Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: A 26-week, multicenter, open-label study

Barker, 2002, Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank, Alzheimer Dis Assoc Disord, 16, 203, 10.1097/00002093-200210000-00001

Cummings, 2003

Lyketsos, 2002, Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: Results from the cardiovascular health study, JAMA, 288, 1475, 10.1001/jama.288.12.1475

Lyketsos, 2000, Mental and behavioral disturbances in dementia: Findings from the Cache County Study on Memory in Aging, Am J Psychiatry, 157, 708, 10.1176/appi.ajp.157.5.708

Mega, 1996, The spectrum of behavioral changes in Alzheimer's disease, Neurology, 46, 130, 10.1212/WNL.46.1.130

Rymer, 2002, Impaired awareness, behavior disturbance, and caregiver burden in Alzheimer disease, Alzheimer Dis Assoc Disord, 16, 248, 10.1097/00002093-200210000-00006

Schulz, 2004, Family caregiving of persons with dementia: Prevalence, health effects, and support strategies, Am J Geriatr Psychiatry, 12, 240, 10.1176/appi.ajgp.12.3.240

Gilley, 2005, Caregiver psychological adjustment and institutionalization of persons with Alzheimer's disease, J Aging Health, 17, 172, 10.1177/0898264304274252

Yaffe, 2002, Patient and caregiver characteristics and nursing home placement in patients with dementia, JAMA, 287, 2090, 10.1001/jama.287.16.2090

Margallo-Lana, 2001, Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments, Int J Geriatr Psychiatry, 16, 39, 10.1002/1099-1166(200101)16:1<39::AID-GPS269>3.0.CO;2-F

Rovner, 1990, The prevalence and management of dementia and other psychiatric disorders in nursing homes, Int Psychogeriatr, 2, 13, 10.1017/S1041610290000266

Draper, 2001, Use of psychotropics in Sydney nursing homes: Associations with depression, psychosis, and behavioral disturbances, Int Psychogeriatr, 13, 107, 10.1017/S1041610201007505

Cummings, 2000, The relationship between donepezil and behavioral disturbances in patients with Alzheimer's disease, Am J Geriatr Psychiatry, 8, 134, 10.1176/appi.ajgp.8.2.134

Cummings, 1996, Neuropsychiatric aspects of Alzheimer's disease: The cholinergic hypothesis revisited, Neurology, 47, 876, 10.1212/WNL.47.4.876

Wynn, 2004, Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease, Dement Geriatr Cogn Disord, 17, 100, 10.1159/000074281

Sink, 2005, Pharmacological treatment of neuropsychiatric symptoms of dementia: A review of the evidence, JAMA, 293, 596, 10.1001/jama.293.5.596

Courtney, 2004, Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): Randomised double-blind trial, Lancet, 363, 2105, 10.1016/S0140-6736(04)16499-4

Tariot, 2001, A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting, J Am Geriatr Soc, 49, 1590, 10.1111/j.1532-5415.2001.49266.x

Ballard, 2005, Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: Randomised double blind placebo controlled trial, BMJ, 330, 874, 10.1136/bmj.38369.459988.8F

Enz, 1993, Brain selective inhibition of acetylcholinesterase: A novel approach to therapy for Alzheimer's disease, Prog Brain Res, 98, 431, 10.1016/S0079-6123(08)62429-2

Corey-Bloom, 1998, A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease, Int J Geriatr Psychopharmacol, 1, 55

Rosler, 1999, Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial [published correction appears in BMJ. 2001;322:1456], BMJ, 318, 633, 10.1136/bmj.318.7184.633

McKhann, 1984, Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease, Neurology, 34, 939, 10.1212/WNL.34.7.939

1994

Folstein, 1975, “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician, J Psychiatr Res, 12, 189, 10.1016/0022-3956(75)90026-6

Rosen, 1980, Pathological verification of ischemic score in differentiation of dementias, Ann Neurol, 7, 486, 10.1002/ana.410070516

Wood, 2000, The use of the neuropsychiatric inventory in nursing home residents. Characterization and measurement, Am J Geriatr Psychiatry, 8, 75, 10.1097/00019442-200002000-00010

Rosen, 1984, A new rating scale for Alzheimer's disease, Am J Psychiatry, 141, 1356, 10.1176/ajp.141.11.1356

Schneider, 1997, Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study, Alzheimer Dis Assoc Disord, 11, 22, 10.1097/00002093-199700112-00004

Cummings, 1993, Physostigmine ameliorates the delusions of Alzheimer's disease, Biol Psychiatry, 33, 536, 10.1016/0006-3223(93)90009-3

Kaufer, 1996, Effect of tacrine on behavioral symptoms in Alzheimer's disease: An open-label study, J Geriatr Psychiatry Neurol, 9, 1, 10.1177/089198879600900101

Morris, 1998, Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease, Neurology, 50, 1222, 10.1212/WNL.50.5.1222

Raskind, 1999, The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients, J Clin Psychiatry, 60, 318, 10.4088/JCP.v60n0510

Raskind, 1997, Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer disease, Arch Neurol, 54, 836, 10.1001/archneur.1997.00550190026010

Tariot, 2000, A 5-month, randomized, placebo-controlled trial of galantamine in AD, Neurology, 54, 2269, 10.1212/WNL.54.12.2269

Bodick, 1997, Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease, Arch Neurol, 54, 465, 10.1001/archneur.1997.00550160091022

Levy, 1999, Neuropsychiatric symptoms and cholinergic therapy for Alzheimer's disease, Gerontology, 45, 15, 10.1159/000052760

Ballard, 2002, Advances in the treatment of Alzheimer's disease: Benefits of dual cholinesterase inhibition, Eur Neurol, 47, 64, 10.1159/000047952

Mesulam, 2000, Neuroanatomy of cholinesterases in the normal human brain and in Alzheimer's disease, 121

Wright, 1993, Neurological cholinesterases in the normal brain and in Alzheimer's disease: Relationship to plaques, tangles, and patterns of selective vulnerability, Ann Neurol, 34, 373, 10.1002/ana.410340312

Anand, 1996, Efficacy and safety results of the early phase studies with Exelon® (ENA-713) in Alzheimer's disease: An overview, J Drug Dev Clin Pract, 8, 109

Fishman, 1986, Distribution of the molecular forms of acetylcholinesterase in human brain: Alterations in dementia of the Alzheimer type, Ann Neurol, 19, 246, 10.1002/ana.410190305

Siek, 1990, Molecular forms of acetylcholinesterase in subcortical areas of normal and Alzheimer disease brain, Biol Psychiatry, 27, 573, 10.1016/0006-3223(90)90524-6

Nordberg, 2000, The effect of cholinesterase inhibitors studies with brain imaging, 237

Potkin, 2001, Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease, Int J Neuropsychopharmacol, 4, 223, 10.1017/S1461145701002528

McKeith, 2000, Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study, Lancet, 356, 2031, 10.1016/S0140-6736(00)03399-7

Reading, 2001, Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: Preliminary findings from an open trial, Mov Disord, 16, 1171, 10.1002/mds.1204

Emre, 2004, Rivastigmine for dementia associated with Parkinson's disease, N Engl J Med, 351, 2509, 10.1056/NEJMoa041470

Billig, 1988, Alzheimer's disease. A psychiatrist's perspective, Nurs Clin North Am, 23, 125, 10.1016/S0029-6465(22)01369-X